Preclinical data of tasquinimod in combination with T cell activation to be presented at ASH 2025

Lund, November 3, 2025 - Active Biotech (NASDAQ STOCKHOLM: ACTI) announced today that an abstract with preclinical data of tasquinimod in combination with T cell activation has been accepted for presentation at the 67th American Society of Hematology Annual Meeting in Orlando, December 6-9, 2025 (ASH 2025). The abstract demonstrating additive efficacy of tasquinimod combined with a T cell enhancer in experimental models of multiple myeloma, will be presented as a poster. The accepted abstracts for ASH 2025 were published today, November 3, 2025.

The abstract, entitled IgG2a-formatted 4-1BB agonism combined with S100A9 inhibition enhances T cell activation and tumor control in a preclinical model of multiple myeloma, will be presented by Hatice Satilmis, Translational Oncology Research Center, Lab of Hematology and Immunology, Vrije Universiteit Brussel, Belgium. The abstract is a result of the collaboration between Active Biotech and Ass Prof Dr Kim de Veirman’s research group at Vrije Universiteit Brussel, Belgium, and aims to support the clinical development of tasquinimod in hematological malignancies.

Data to be presented demonstrate the enhancement of the anti-tumor effect of T cell activation when combined with tasquinimod. The tumor cells were further decreased, and immune cells such as T and NK cells became more active, leading to an increased therapeutic effect.

“The immune suppressive bone marrow limits the effect of immunotherapy such as T cell activation in multiple myeloma. Data to be presented suggest increased therapeutic efficacy of a T cell activator when combined with tasquinimod in a model of multiple myeloma. This highlights tasquinimod's ability to restore antitumor immunity within the tumor microenvironment and is also relevant for other hematological cancers,” said Marie Törngren, VP R&D at Active Biotech.

Information on the presentation:

Publication Number: 5696 IgG2a-formatted 4-1BB agonism combined with S100A9 inhibition enhances T cell activation and tumor control in a preclinical model of multiple myeloma

Session Name: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III

Session Date: Monday, December 8, 2025

Presentation Time: 6:00 PM - 8:00 PM (local time)

Location: Orlando Convention Center, West Halls B3-B4

The abstracts will be available online on ASH’s website from 09:00 Eastern time (15:00 CET) on November 3, 2025.